AVIR
Atea Pharmaceuticals, Inc.
$4.74
+0.04
(+0.85%)
Mkt Cap
376.13M
Volume
46,020
52W Range
2.78-6.45
Sector
Healthcare
Beta
0.32
EPS (TTM)
-2.11
P/E Ratio
-1.84
Revenue (TTM)
0
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
AlphaVal · Fair Value
What we estimate one share is worth
$28.77
Undervalued
strong signal
83.7% below fair value
Modeled from cash flows & growth.
AlphaQuality · Grade · Gated
How strong & durable the business is
F
Stable Earnings Power
30.0 / 100 pillar composite (overridden)
Steady, predictable earnings power — graded A–F vs. similar companies.
Company Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 351.37M | 48.63M | 0 | 0 |
| Net Income | (158.35M) | (168.38M) | (135.96M) | (115.91M) | 121.19M | (10.95M) | (13.46M) | (9.06M) |
| EPS | -1.94 | -2.00 | -1.63 | -1.39 | 1.46 | -0.13 | -0.16 | -0.90 |
| Free Cash Flow | (132.03M) | (135.50M) | (85.39M) | (122.92M) | (87.01M) | 296.71M | (12.82M) | (7.92M) |
| FCF / Share | -1.62 | -1.61 | -1.02 | -1.48 | -1.05 | 3.60 | -0.16 | -0.78 |
| Operating CF | (132.03M) | (135.50M) | (85.39M) | (120.98M) | (87.00M) | 296.73M | (12.81M) | (7.91M) |
| Total Assets | 315.22M | 464.67M | 594.97M | 666.71M | 772.89M | 863.63M | 22.07M | 34.86M |
| Total Debt | 843,000 | 1.64M | 2.40M | 3.12M | 197,000 | 0 | 0 | 0 |
| Cash & Equiv | 95.71M | 64.70M | 143.82M | 646.71M | 764.38M | 850.12M | 21.66M | 34.49M |
| Book Value | 275.43M | 438.87M | 555.19M | 640.57M | 710.08M | 547.80M | 19.54M | (36.16M) |
| Return on Equity | -0.57 | -0.38 | -0.24 | -0.18 | 0.17 | -0.02 | -0.69 | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (45.44M) | (44.87M) | (42.05M) | (37.16M) | (34.27M) | (33.54M) | (31.15M) | (40.52M) | (63.17M) | (39.16M) | (33.14M) | (28.18M) |
| EPS | -0.57 | -0.57 | -0.53 | -0.44 | -0.40 | -0.40 | -0.37 | -0.48 | -0.75 | -0.47 | -0.40 | -0.34 |
| Free Cash Flow | (46.39M) | (28.22M) | (40.38M) | (32.87M) | (30.56M) | (30.40M) | (23.04M) | (42.20M) | (39.87M) | (21.83M) | (17.59M) | (16.12M) |
| FCF / Share | -0.59 | -0.36 | -0.51 | -0.39 | -0.36 | -0.36 | -0.27 | -0.50 | -0.48 | -0.26 | -0.21 | -0.19 |
| Operating CF | (46.39M) | (28.22M) | (40.38M) | (32.87M) | (30.56M) | (30.40M) | (23.04M) | (42.20M) | (39.87M) | (21.83M) | (17.59M) | (16.12M) |
| Total Assets | 267.08M | 315.22M | 342.96M | 391.61M | 439.96M | 464.67M | 490.96M | 510.38M | 553.03M | 594.97M | 608.08M | 626.03M |
| Total Debt | 634,000 | 843,000 | 1.04M | 1.25M | 1.45M | 1.64M | 1.83M | 2.02M | 2.21M | 2.40M | 2.58M | 2.77M |
| Cash & Equiv | 79.32M | 95.71M | 77.34M | 87.72M | 119.39M | 64.70M | 98.46M | 243.39M | 160.91M | 143.82M | 137.89M | 213.70M |
| Book Value | 233.71M | 275.43M | 315.78M | 364.42M | 411.08M | 438.87M | 458.52M | 476.47M | 504.37M | 555.19M | 581.73M | 602.35M |
| Return on Equity | -0.19 | -0.16 | -0.13 | -0.10 | -0.08 | -0.08 | -0.07 | -0.09 | -0.13 | -0.07 | -0.06 | -0.05 |
AVIR News
Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus
Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
Atea Pharmaceuticals (AVIR) Upgraded to Buy: Here's What You Should Know
Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year?
Atea Pharmaceuticals: I'm Optimistic Ahead Of Critical HPV Catalyst
Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026
Down 25% in 4 Weeks, Here's Why Atea Pharmaceuticals (AVIR) Looks Ripe for a Turnaround
Atea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline
Atea Pharmaceuticals, Inc. (AVIR) Q1 2026 Earnings Call Transcript
Atea Pharmaceuticals Q1 Earnings Call Highlights